Research Agreements (Details)	0 Months Ended	3 Months Ended		9 Months Ended						9 Months Ended				3 Months Ended			3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended				3 Months Ended		9 Months Ended		1 Months Ended			1 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended												1 Months Ended		9 Months Ended		0 Months Ended			0 Months Ended	9 Months Ended		0 Months Ended		1 Months Ended
	Jun. 11, 2014	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2014 Series A-5 Convertible Preferred Stock USD ($)	Dec. 31, 2013 Series A-5 Convertible Preferred Stock	Sep. 30, 2014 Series A-6 Convertible Preferred Stock USD ($)	Dec. 31, 2013 Series A-6 Convertible Preferred Stock	Sep. 30, 2014 Clinical Trial Services Agreement Pass-through costs USD ($)	Sep. 30, 2013 Clinical Trial Services Agreement Pass-through costs USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Maximum USD ($) item	Sep. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Maximum EUR (€)	Sep. 30, 2014 Clinical Trial Services Agreement USD ($)	Sep. 30, 2013 Clinical Trial Services Agreement USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Maximum Per patient costs for enrolled patients	Sep. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Minimum Per patient costs for enrolled patients	Sep. 30, 2014 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2013 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Per patient costs for enrolled patients USD ($)	Sep. 30, 2013 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Per patient costs for enrolled patients USD ($)	Feb. 28, 2014 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Nordic Maximum USD ($)	Feb. 28, 2014 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Nordic Maximum EUR (€)	Dec. 31, 2013 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Nordic Series A-6 Convertible Preferred Stock	Feb. 28, 2014 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Nordic Series A-6 Convertible Preferred Stock Maximum USD ($)	Dec. 31, 2013 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Nordic Common Stock	Mar. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum USD ($)	Mar. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum EUR (€)	Sep. 30, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum EUR (€)	Mar. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Series A-6 Convertible Preferred Stock Maximum USD ($)	Mar. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Series A-6 Convertible Preferred Stock Maximum EUR (€)	Sep. 30, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Series A-6 Convertible Preferred Stock Maximum USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Series A-6 Convertible Preferred Stock Maximum EUR (€)	Sep. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Study United States item	Sep. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Study United States Maximum USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Study United States Maximum EUR (€)	Sep. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Study India item	Sep. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Study India Maximum USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Study India Maximum EUR (€)	Sep. 30, 2014 Clinical Trial Services Agreement Second Amendment Abaloparatide-SC Phase 3 Clinical Study USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Second Amendment Abaloparatide-SC Phase 3 Clinical Study EUR (€)	Sep. 30, 2014 Clinical Trial Services Agreement Second Amendment Abaloparatide-SC Phase 3 Clinical Study Maximum USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Second Amendment Abaloparatide-SC Phase 3 Clinical Study Maximum EUR (€)	Mar. 31, 2014 Clinical Trial Services Agreement Fourth Amendment Abaloparatide-SC Phase 3 Clinical Study Nordic USD ($) item	Mar. 31, 2014 Clinical Trial Services Agreement Fourth Amendment Abaloparatide-SC Phase 3 Clinical Study Nordic Maximum USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Nordic Series A-6 Convertible Preferred Stock USD ($) item	Mar. 31, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Nordic Series A-6 Convertible Preferred Stock	May 17, 2011 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Study Nordic Series A-5 Convertible Preferred Stock USD ($)	Mar. 29, 2011 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Study Nordic Series A-5 Convertible Preferred Stock EUR (€)	May 17, 2011 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Study Nordic Series A-5 Convertible Preferred Stock USD ($)	May 17, 2011 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Study Nordic Series A-5 Convertible Preferred Stock Former Operating Company	Sep. 30, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Study Nordic Series A-6 Convertible Preferred Stock Maximum USD ($)	Sep. 30, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Study Nordic Series A-6 Convertible Preferred Stock Maximum EUR (€)	Dec. 06, 2013 Clinical Trial Services Agreement Letter of Intent Abaloparatide-SC Phase 3 Extension Clinical Study Nordic USD ($)	Dec. 06, 2013 Clinical Trial Services Agreement Letter of Intent Abaloparatide-SC Phase 3 Extension Clinical Study Nordic EUR (€)	Oct. 31, 2012 Clinical Trial Services Agreement Letter of Intent Abaloparatide-SC Phase 3 Extension Clinical Study Nordic USD ($)	Oct. 31, 2012 Clinical Trial Services Agreement Letter of Intent Abaloparatide-SC Phase 3 Extension Clinical Study Nordic EUR (€)
Research Agreements
Number of additional study sites																																												5			15
Final payments, number of euro-denominated installments												2	2
Final payments, number of U.S dollar-denominated installments												2	2
Amount of euro-denominated payments required over the course of Clinical Trial												$ 52,000,000	€ 41,200,000																		$ 4,500,000	€ 3,600,000				$ 3,700,000	€ 3,000,000	$ 9,500,000	€ 7,500,000						$ 1,600,000	€ 1,200,000		$ 906,312	€ 717,700			$ 4,700,000	€ 3,700,000
Amount of U.S. dollar-denominated payments required over the course of Clinical Trial												3,200,000																			300,000					527,740		1,100,000							143,369			289,663				205,540
Value of shares agreed to be purchased																																																											371,864
Purchase price per share of convertible preferred stock (in dollars per share)						$ 81.42		$ 81.42																																																				$ 8.142
Additional term provided for standard-of-care treatment																																																																18 months	18 months
Dividend declared (in shares)																																	32,215																								186,847
Stock dividends declared																																																								29
Number of shares issued						0	6,443	0	496,111																																															186,847
Payments owed to be changed from the right to receive stock to the right to receive cash payment, if an IPO occurs prior to May 31, 2014																																																								4,300,000
Number of equal monthly installments for cash payments																																																								10
Amount of equal monthly installments for cash payments																																																								430,000
Shares sold	6,500,000																																																									64,430
Proceeds from issuance of shares																																																										525,154
Number of shares exchanged in the Merger																																																													6,443
Aggregate value of quarterly stock dividends, payable in shares																																		2,900,000						3,700,000	3,000,000	9,500,000	7,500,000																			46,500,000	36,800,000
Aggregate U.S. dollar value of quarterly stock dividends, payable in shares																																								527,740		800,000
Number of shares due to the counter party																																	32,215
Number of shares due to the counter party after conversion of stock																																			141,294
Amount reflected in accrued expenses and other current liabilities resulting from services payable in cash																9,500,000					4,500,000		4,500,000
Amount of initial payments for Euro-denominated installments																																																																300,000	222,573	1.0	806,468
Maximum aggregate amount of additional payments												5,000,000																																											5,000,000
Amount of additional performance incentive payable to every specified patient																																																						500,000
Number of patients to whom additional performance incentive is payable																																																						50
Period for which research and development expense is recognized																			20 months						19 months	9 months			9 months
Research and development expense		13,817,000	15,543,000	34,152,000	49,070,000					800,000	3,300,000			300,000	1,300,000		1,200,000	7,600,000	8,100,000	25,500,000	2,300,000	1,300,000	7,700,000	2,600,000			0	600,000	0	4,100,000
Reduction in amount of euro-denominated payments required over the course of clinical study																																																		$ 15,079	€ 11,941